Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile

Ocrelizumab therapy and long-term outcomes in multiple sclerosis: clinical and MRI-efficacyand safety profile

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the treatment of adults with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The article presents data on the clinical and MRI efficacy and safety profile of ocrelizumab for the lon...

Full description

Bibliographic Details
Main Authors: D. L. Klabukova, M. V. Davydovskaya
Format: Article
Language:Russian
Published: Remedium Group LLC 2019-06-01
Series:Медицинский совет
Subjects:
ocrelizumab
multiple sclerosis
efficacy
safety
long-term outcomes
Online Access:https://www.med-sovet.pro/jour/article/view/3036

Internet

https://www.med-sovet.pro/jour/article/view/3036

Similar Items